What's In Store For You? 

Advanced Therapies Europe 2025 offers a unique opportunity for professionals working in cell and gene therapy to connect with biotech leaders, pharma, regulators, and investors — the full ecosystem needed to turn early-stage science into patient-ready solutions.

Whether you're seeking industry partnerships, insight into regulatory pathways, or funding opportunities, this is your platform to move your research forward.

  • Build translational partnerships with leading biotech and pharma

  • Stay ahead of evolving regulatory and clinical frameworks

  • Learn from peers scaling academic-led CGT manufacturing and innovation

Apply to attend

Key themes to discover...

  • Innovative Trial Design for Investigator-Led Studies: Gain exposure to the latest thinking in CGT trial methodologies to enable you to design more effective and fundable investigator-led studies.

  • Pathways to First-in-Human Trials: Discover how peers moved from lab to first-in-human studies providing a roadmap to clinical validation for your work.

  • Optimising Clinical Protocols for CGT Trials: Share and learn best practices for patient selection, administration, and monitoring to improve safety and effectiveness in your own trials.

  • Translational Partnerships & Funding Opportunities: Meet biotechs and regulators actively looking to partner with academic innovators and open new translational funding and collaboration opportunities.

Your Personalised Itinerary

09:55
  1. Plenary

    Deep dive into the regulatory framework that governs CGT across major rejoins, focusing on recent updates, new legislation and how companies can navigate the changing landscape.

10:25
  1. Plenary
    A conversation with key patient advocates and organisations to highlight the importance of patient engagement, access, and ensuring therapies meet real-world needs in CGT.
11:30
    • R&D, clinical innovation & translation
    Theatre 1
    • Cutting edge developments in CRISPR, gene editing and cell engineering
    • The next wave of in vivo and ex vivo gene therapies
    • What breakthroughs are expected to reshape the industry?
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • As the pressure mounts to deliver advanced therapies faster, cheaper, and closer to the patient, decentralised manufacturing is stepping into the spotlight. But does breaking away from centralised models really deliver on cost? 

    • This panel dives into the economic realities behind the decentralisation trend. Are localised manufacturing hubs the answer to cutting costs, or do they introduce new layers of complexity and hidden spend? From infrastructure investments to regulatory headaches, we’ll separate financial fact from fiction and explore whether decentralisation is a bold leap forward or an expensive detour. 

12:25
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
12:50
    • R&D, clinical innovation & translation
    Theatre 1
    • Scientific advances and key breakthroughs.
    • Safety, efficacy, and regulatory challenges.
    • Investment trends and commercialisation potential.
14:30
    • Manufacturing, scale up & commercial strategy
    Theatre 2
    • Transitioning from academic proof of concept to market-ready product 

    • Why biotech teams must integrate CMC, regulatory and pharmacology early 

    • Avoiding pitfalls of overselling and overpromising 

15:05
    • R&D, clinical innovation & translation
    Theatre 1
    • Why characterisation and analytics remain a major hurdle. 

    • Collaborative approaches to tackling technical challenges 

    • Best practices and emerging solutions. 

    • Manufacturing, scale up & commercial strategy
    Theatre 2
    Discuss the key challenges in patient-centric manufacturing, focusing on ensuring timely delivery of therapies, managing logistics, and addressing issues related to personalised treatments, from patient selection to product delivery. 
15:40
    • Manufacturing, scale up & commercial strategy
    Theatre 2
16:00
    • Manufacturing, scale up & commercial strategy
    Theatre 2
11:30
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
14:00
    • R&D, clinical innovation & translation
    Theatre 1
    • Manufacturing, scale up & commercial strategy
    Theatre 2
14:20
    • R&D, clinical innovation & translation
    Theatre 1
15:15
  1. Plenary

    AI is everywhere, but in CGT, real deployment remains limited. This session goes beyond the buzz to explore the tangible opportunities, early wins, and critical barriers to broader adoption. 

    We’ll look at where AI is beginning to make a difference and what’s still needed to move from isolated pilots to real impact. What kind of data, infrastructure, and cross-functional collaboration will unlock AI’s full potential in CGT? 

16:00
  1. Plenary
    As we wrap up two days of deep discussions on the current state of the European CGT landscape, this final panel will chart the path ahead. Which steps must Europe take to remain competitive and lead the way in the next 5–10 years? Each panellist will share their key takeaways from the last two days, reflecting on the insights, challenges, and opportunities discussed. 

Discover Advanced Therapies Week as an academic

Discover how Advanced Therapies Europe empowers academic researchers to turn groundbreaking science into real-world impact. From connecting with biotech and pharma leaders to understanding the latest regulatory pathways and funding opportunities, this is where academic innovation moves closer to the clinic.

Content Packed Agenda

Gain insights, meet investors, and accelerate your path to commercialization.

State of the Art Networking

Discover promising companies, network with peers, and explore new opportunities.

Unlock Funding Opportunities

Meet funders and explore translational grants designed to move your research from lab to clinic.

Shape the Future of CGT

Join discussions on the critical role of academia in driving early-stage innovation and equitable access.

Who Might You Find On the Show Floor?

Sample Attendee List Current Exhibitor List

500+
Attendees
40+
Companies
150+
Speakers
170+
Therapeutic Developers

 

  • "What an incredible few days at the ATE conference by Phacilitate! Grateful for the power of my network and the opportunity to meet so many familiar faces while growing it further.”
    Head of Business Development: Cell Therapy and Laboratory Services | Cell and Gene Therapy
  • “Impactful moments and connections.”
    Director Global Cell and Gene Therapies Portfolio Management | EMBA | Deep Tech
  • “Already having fantastic conversations here at ATE24 in Lisbon.”
    Experienced Leader in Cell and Gene Therapy Business and Commercial Strategy